HIV/HCV Co-Infection Watch: 2017 Annual Monitoring Report



The HIV/HCV Co-Infection Watch is a publication of the Community Access National Network (CANN). It is a patient-centric informational portal serving three primary groups – Patients, Healthcare Providers, and AIDS Service Organizations.

Learn more: http://www.tiicann.org



Community Access National Network (CANN) – National Monitoring Report on HIV/HCV Co-Infection– Page 1

Background

- Launched in January 2015
- Monthly summary on relevant data on co-infection of human immunodeficiency virus (HIV) and hepatitis C (HCV)
- Initially, limited focus on:
 - AIDS Drug Assistance Programs
 - Medicaid
 - Latest News related to HIV/HCV and Co-Infection
- Subsequently, expanded focus on:
 - Veterans
 - Harm Reduction
 - Regional Trends

<u>Background – What's included</u>


- Overview
- Findings
- AIDS Drug Assistance Programs (ADAPs)
- Medicaid Programs
- Veterans Programs
- Harm Reduction Programs
- Regional Trends
- Latest News
- Contact Information
- Disclaimer
- Methodology
- References

ADAP HCV DAA Trends: 2015-2017

Coverage Trends


- January 2015:
 - States offering Expanded Coverage 7 (CA, CO, HI, IA, MA, MN, NJ) ٠
 - States offering only Basic Coverage 24
- June 2015:
 - States offering Expanded Coverage 11 (AZ, AR, CA, CO, HI, IA, LA, MA, MN, NJ, SD)
 - States offering only Basic Coverage 24 ٠
- January 2016:
 - States offering Expanded Coverage 17 (AZ, AR, CA, CO, DE, HI, IA, ME, MA, MN, NJ, OK, PA, TN, VA, WA, DC) ٠
 - States offering only Basic Coverage 18
- June 2016:
 - States offering Expanded Coverage 26 (AZ, AR, CA, CO, DE, FL, GA, HI, IL, IA, LA, ME, MD, MA, MN, NE, NH, NJ, OK, PA, SD, TN, VA, WA, DC, PR)
 - States offering only Basic Coverage 16
- January 2017:
 - States offering Expanded Coverage 29 (AZ, AR, CA, CO, DE, FL, GA, HI, IL, IA, LA, ME, MD, MA, MN, NE, NH, NJ, NY, OK, OR, PA, SD, TN, VA, WA, WI, DC, PR)
 - States offering only Basic Coverage 13
- August 2017:
 - States offering expanded coverage 33 (AZ, AR, CA, CO, DE, FL, GA, HI, IL, IA, LA, ME, MD, MA, MN, MO, MT, NE, NH, NJ, NY, ND, OK, • OR, PA, SD, TN, TX, VA, WA, WI, DC, PR)
 - States offering only Basic Coverage 12 •
- States have continued to expand coverage as newer, cheaper HCV DAAs hit the market.
- Expansion has slowed significantly over the past year
- Harvoni, Zepatier, and Viekira Pak are the most covered drugs 29, 28, & 26, respectively _
- Olysio and Viekira XR are the least covered drugs 19 & 18, respectively _
- Mavyret's WAC of \$39,600 for 12 weeks, \$26,400 for 8 weeks

ADAP Expanded Coverage: January 2015 - June 2015






ADAP Expanded Coverage: January 2016 – June 2016






ADAP Expanded Coverage: January - August 2017





ADAP HCV Drug Utilization: January 2015 – August 2017


ADAP HCV Drug Adoption: January 2015 - August 2017





HCV Rates Compared to ADAP Coverage

Ten Highest Rates of HCV Infection (2015)		
1	Massachusetts	3.7
2	West Virginia	3.4
3	Kentucky	2.7
4	Tennessee	2.6
5	Maine	2.3
6	Indiana	2.1
7	New Mexico	1.9
8	Montana	1.5
	New Jersey	1.5
9	Alabama	1.4
	North Carolina	1.4
10	Ohio	1.1
	Wisconsin	1.1






2015-2017 Trends: Medicaid

Coverage Trends


- January 2015:
 - States offering Expanded Coverage 38
 - States offering only Basic Coverage 12 (AK, AR, CA, CT, FL, KS, MI, NM, ND, RI, SC, TX)
- June 2015:
 - States offering Expanded Coverage 39
 - States offering only Basic Coverage 11 (AR, CA, CT, FL, KS, MI, NM, ND, SC, TX, WA)
- January 2016:
 - States offering Expanded Coverage 49
 - States offering only Basic Coverage 2 (AR, MI)
- June 2016:
 - States offering Expanded Coverage 50
 - States offering only Basic Coverage 1 (AR)
- August 2016 August 2017:
 - States offering Expanded Coverage 51
 - States offering only Basic Coverage 0
- All states currently offer Expanded Coverage for HCV drugs
- Medicaid programs quicker to adopt HCV drugs than ADAPs
- States with multiple coverage plans are likelier to have plans offering only one or two HCV DAAs

Medicaid Expanded Coverage: January 2015 – June 2015






Medicaid Expanded Coverage: January 2016 – June 2016






Medicaid Expanded Coverage: August 2016 – August 2017



Medicaid HCV Drug Utilization



-Infection Watch

2017 Trends: Veterans Affairs

• Coverage Trends:

- The Report began covering VA HCV coverage in March 2016
- Coincided with VA announcement of universal coverage for all eligible VA members
- Most-used drugs: Epclusa (16); Harvoni (10); Zepatier (10)
- VA continues to provide most effective treatment program in government-funded healthcare




2017 Trends: Harm Reduction

- Harm Reduction measures becoming more popular:
 - Syringe Services Programs (SSPs)
 - Expanded Naloxone Access
- CDC Public Health Law Program site for Prescription Drugs not updated since August 2015:
 - Data difficult to track
 - Reports outdated
- Primary barriers to Harm Reduction Measures:
 - Syringe Exchange:
 - Data vs. Perception
 - "Enabling"
 - "Condoning"
 - Safety/Biohazardous Waste
 - Mandatory PDMP Use:
 - Physician/Pain Advocate opposition
 - Outdated software/interface / User unfriendly
 - "Time hassle"

2017 Trends: Harm Reduction

- Primary barriers to Harm Reduction Measures:
 - Doctor Shopping:
 - Federal blanket statute
 - Reporting/Checking hassle
 - Physical Exam Requirement:
 - Physician/Pain Advocate opposition
 - "Too time consuming"
 - "Too onerous"
 - Patient mobility/barriers to accessing care/treatment
 - ID Requirement for Purchase of Prescription Opioid Drugs:
 - Pain Advocate opposition
 - "Burden on poor/minority patients"
 - Hardware update costs for scanning
 - "Government tracking"
 - Prescriber Education:
 - Physician opposition
 - "Time consuming"
 - Pharmacy Lock-In Programs:
 - Outdated/User unfriendly software/interface
 - Paid Advocate opposition "Barrier to accessing care/treatment"

Harm Reduction Measures: August 2016 vs. 2017



Contact Information

Community Access National Network (CANN)

1724 Florida Avenue, NW

Washington, DC 20009

(202) 290-2019

www.tiicann.org

http://www.tiicann.org/co-infection-watch.html

Bill Arnold, President & CEO

weaids@tiicann.org

Marcus J. Hopkins, Project Director mhopkins@tiicann.org

